Search Within

Sarcoma Service

Formats
  1. Journal Article (455)
  2. Meeting Abstract (431)
  3. Review (29)
  4. Editorial (9)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (953)
  2. Solid Tumor Oncology Division (953)
  3. GSK Faculty (343)
  4. Tow Center for Developmental Oncology (TCDO) (310)
  5. Hematologic Malignancies, Division of (295)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. William Tap (382)
  2. Sandra D'Angelo (256)
  3. Mrinal Gounder (232)
  4. Ping Chi (177)
  5. Mark Dickson (173)
  6. Cristina Antonescu (138)

More People

Years
  1. 2025 (44)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (274)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (61)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (28)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (288)
  2. American Association for Cancer Research (108)
  3. Oxford University Press (92)
  4. Elsevier Inc. (57)
  5. Nature Publishing Group (42)
  6. Springer (40)

More Publishers

Results (953)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
    Meeting Abstract

    LoRusso, P.; Gounder, M. M.; Yamamoto, N.; Patel, M. R.; Bauer, T. M.; Geng, J.; Sailer, R.; Tang, Y.; Jayadeva, G.; Schöffski, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort
    Meeting Abstract

    Movva, S.; Druta, M.; Davis, L. E.; Monga, V.; Milhem, M. M.; Bailey, H. H.; Chugh, R.; Bruns, I.; Allgood, V. E.; Chawla, S. P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors
    Meeting Abstract

    Alcindor, T.; Kasper, B.; Gounder, M. M.; Ratan, R.; Van Der Graaf, W. T. A.; Wilky, B. A.; Riedel, R. F.; Federman, N.; Peruzzi, A.; Moody, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results
    Meeting Abstract

    Gounder, M. M.; Jones, R. L.; Chugh, R.; Agulnik, M.; Singh, A. S.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J. H.; Ratan, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; Chan, J. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902)
    Meeting Abstract

    Grilley-Olson, J. E.; Allred, J. B.; Schuetze, S.; Davis, E. J.; Wagner, M. J.; Poklepovic, A. S.; Waechter, B.; Riedel, R. F.; Welliver, M. X.; Berg, S. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Redefining early-onset cancer and risk of hereditary cancer predisposition
    Meeting Abstract

    Stadler, Z. K.; Maio, A.; Khurram, A.; Kemel, Y.; Padunan, A.; Borio, M.; Sheehan, M.; Murciano-Goroff, Y. R.; Walsh, M. F.; Will, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist
    Meeting Abstract

    Peltzer, A.; Hesse, R.; Gounder, M. M.; Yamamoto, N.; Patel, M. R.; Laurie, S.; Bauer, T. M.; Teufel, M.; Geng, J.; LoRusso, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Meeting Abstract

    Barker, C. A.; D'Angelo, S. P.; Steckler, A. M.; Lian, M.; Wasilewski, G.; Lacouture, M. E.; Chapman, P. B.; Shoushtari, A. N.; Ariyan, C. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save